Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

CURIS INC Director's Dealing 2007

Aug 15, 2007

34952_dirs_2007-08-15_f4ede506-b686-48c7-adc9-ae7c24aaa3e5.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: CURIS INC (CRIS)
CIK: 0001108205
Period of Report: 2007-08-08

Reporting Person: RA CAPITAL MANAGEMENT, LLC (10% Owner)
Reporting Person: ALDRICH RICHARD (10% Owner)
Reporting Person: Kolchinsky Peter (10% Owner)
Reporting Person: RA Capital Biotech Fund II, L.P. (10% Owner)
Reporting Person: RA Capital Biotech Fund LP (10% Owner)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 7520564 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Warrants to Purchase Common Stock $1.02 2012-08-08 Common Stock (2632198) Indirect

Footnotes

F1: These shares represent 7,388,202 shares held by RA Capital Biotech Fund, L.P. ("Fund I"), and 132,362 shares held by RA Capital Biotech Fund II, L.P. ("Fund II"). RA Capital Management, LLC (the "General Partner") is the general partner of each of Fund I and Fund II, and Richard H. Aldrich and Peter Kolchinsky are the sole managers of RA Capital Management, LLC. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.

F2: These warrants are exerciseable for cash, provided, however, that the warrants are not exerciseable to the extent the holder of any such warrant, together with any affiliates, holds or beneficially owns more than 9.99% of the outstanding Common Stock of the issuer, unless such restriction is waived by the holder upon not less than 61 days written notice to the issuer.

F3: These warrants represent the right for RA Capital Biotech Fund, L.P. ("Fund I") to acquire 2,585,871 additional shares of Common Stock and for RA Capital Biotech Fund II, L.P. ("Fund II") to acquire 46,327 additional shares of Common Stock, in each case upon the terms and conditions set forth in such warrant. RA Capital Management, LLC (the "General Partner") is the general partner of each of Fund I and Fund II, and Richard H. Aldrich and Peter Kolchinsky are the sole managers of RA Capital Management, LLC. Each of the Reporting Persons disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein, if any.